摘要
目的观察氟伐他汀联合天保宁对冠心病的治疗效果,关注其对血清中基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)和基质金属蛋白酶-14(MMP-14)的作用。方法收集我院诊治的冠心病患者共138例,分为对照组和观察组各69例。对照组应用常规治疗,观察组在上述基础上加用氟伐他汀联合天保宁进行治疗。观察两组的疗效及治疗3个月后、6个月后对血清中MMP-2、MMP-9和MMP-14的影响。结果观察组的显效率明显高于对照组,两组治疗3个月时血清中MMP-2、MMP-9和MMP-14的下调作用不明显,而治疗6个月后观察组血清中MMP-2、MMP-9和MMP-14下降更明显。结论应用氟伐他汀联合天保宁治疗冠心病的疗效明显,于治疗6个月后对血清中MMP-2、MMP-9和MMP-14的表达有下调作用,临床治疗中可以积极应用。
Objective To investigate the effect and changes of MMP-2, MMP-9 and MMP-14 in patients with coronary heart disease by fluvastatin and taponin. Methods The 138 patients with coronary heart disease were divided into two groups. The control group （69 cases） was treated by routine treatment. The observation group was divided by routine treatment, fluvastatin and taponin. The effect was observed in two groups. The changes of MMP-2, MMP-9 and MMP- 14 were observed in two groups in 3 months and 6 months. Results The effective rate was higher in the observation group than in the control group. The expressions of MMP-2, MMP-9 and MMP-14 were not changed in the observation group than in the control group after 3 months treatment. The expressions of MMP-2, MMP-9 and MMP-14 were lower in the observation group than in the control group after 6 months treatment. Conclusion Fluvastatin and taponin can in- crease the clinical effect, decrease the expressions of MMP-2, MMP-9 and MMP-14 （6 months treatment） in patients with coronary heart disease, is worthy be applied in clinical treatment.
出处
《中国现代医生》
2014年第10期45-47,共3页
China Modern Doctor
基金
浙江省医学会临床科研基金(2009ZYC18)
